Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ablynx Collaborates with Centocor R&D | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Ablynx Collaborates with Centocor R&D

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ablynx has signed a collaboration agreement with Centocor R&D, Inc. under which the companies will perform research funded by Centocor. Applying the unique properties of Nanobodies, the two companies will work jointly on novel approaches for administration and delivery of Nanobody-based therapeutics. The financial terms of the collaboration are not disclosed.

Nanobodies are a novel class of therapeutic proteins that combine the beneficial features of conventional antibodies with desirable properties of small molecule drugs. Because of their unique structure and high stability, Nanobodies can address target opportunities that are beyond the reach of conventional antibodies.

Dr. Mark Vaeck, chief executive officer of Ablynx said, “We are delighted to engage in this collaboration with Centocor who are a pioneer in the development of therapeutic antibodies. Through this partnership we create a unique opportunity for Ablynx, by combining our own know-how on the Nanobody platform with the world-class expertise of Centocor, who are considered as the benchmark in therapeutic antibody development.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics